Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Prevalence and differentiation of hereditary breast and ovarian cancers in Japan.

Nakamura S, Takahashi M, Tozaki M, Nakayama T, Nomizu T, Miki Y, Murakami Y, Aoki D, Iwase T, Nishimura S, Yamauchi H, Ohsumi S, Baba S, Shimizu T.

Breast Cancer. 2015 Sep;22(5):462-8. doi: 10.1007/s12282-013-0503-1. Epub 2013 Nov 19.

PMID:
24249303
2.

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.

de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P.

Fam Cancer. 2015 Dec;14(4):505-13. doi: 10.1007/s10689-015-9814-z.

PMID:
26026974
3.

Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.

Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D, Santibáñez M, Blazer KR, Weitzel JN.

Cancer. 2015 Feb 1;121(3):372-8. doi: 10.1002/cncr.29058. Epub 2014 Sep 18.

4.

Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.

Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K.

BMC Cancer. 2008 May 20;8:140. doi: 10.1186/1471-2407-8-140.

5.

Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.

Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, Shakoori AR, Seidel-Renkert A, Farooq H, Narod S, Amin A, Hamann U.

Int J Cancer. 2006 Dec 15;119(12):2832-9.

6.

Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.

de Juan Jiménez I, García Casado Z, Palanca Suela S, Esteban Cardeñosa E, López Guerrero JA, Segura Huerta Á, Chirivella González I, Sánchez Heras AB, Juan Fita MJ, Tena García I, Guillen Ponce C, Martínez de Dueñas E, Romero Noguera I, Salas Trejo D, Goicoechea Sáez M, Bolufer Gilabert P.

Fam Cancer. 2013 Dec;12(4):767-77. doi: 10.1007/s10689-013-9622-2.

PMID:
23479189
7.

Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.

Stadler ZK, Saloustros E, Hansen NA, Schluger AE, Kauff ND, Offit K, Robson ME.

Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11.

PMID:
20221693
8.

Incorporating tumour pathology information into breast cancer risk prediction algorithms.

Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC.

Breast Cancer Res. 2010;12(3):R28. doi: 10.1186/bcr2576. Epub 2010 May 18.

9.

Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.

Sekine M, Nagata H, Tsuji S, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, Nagata I, Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto T, Motoyama S, Tanaka K; Japanese Familial Ovarian Cancer Study Group.

Clin Cancer Res. 2001 Oct;7(10):3144-50.

10.

Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.

Janavičius R, Rudaitis V, Mickys U, Elsakov P, Griškevičius L.

Cancer Genet. 2014 May;207(5):195-205. doi: 10.1016/j.cancergen.2014.05.002. Epub 2014 May 10.

PMID:
25066507
11.

Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.

Rudnicka H, Debniak T, Cybulski C, Huzarski T, Gronwald J, Lubinski J, Gorski B.

Mol Biol Rep. 2013 Dec;40(12):6619-23. doi: 10.1007/s11033-013-2775-0. Epub 2013 Sep 25.

PMID:
24065545
12.

Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.

Pylkäs K, Erkko H, Nikkilä J, Sólyom S, Winqvist R.

BMC Cancer. 2008 May 26;8:146. doi: 10.1186/1471-2407-8-146.

13.

Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.

Konecny M, Milly M, Zavodna K, Weismanova E, Gregorova J, Mlkva I, Ilencikova D, Kausitz J, Bartosova Z.

Breast Cancer Res Treat. 2011 Feb;126(1):119-30. doi: 10.1007/s10549-010-1325-x. Epub 2011 Jan 4.

PMID:
21203900
14.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

15.

Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.

Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ.

Breast Cancer Res Treat. 2015 Jan;149(1):223-7. doi: 10.1007/s10549-014-3218-x. Epub 2014 Dec 6. Erratum in: Breast Cancer Res Treat. 2015 May;151(1):233.

PMID:
25476495
16.

BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.

Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P.

Dis Markers. 2012;32(6):343-53. doi: 10.3233/DMA-2012-0893.

17.

Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.

Blanco A, de la Hoya M, Osorio A, Diez O, Miramar MD, Infante M, Martinez-Bouzas C, Torres A, Lasa A, Llort G, Brunet J, Graña B, Perez Segura P, Garcia MJ, Gutiérrez-Enríquez S, Carracedo Á, Tejada MI, Velasco EA, Calvo MT, Balmaña J, Benitez J, Caldés T, Vega A.

PLoS One. 2013 Jul 23;8(7):e67538. doi: 10.1371/journal.pone.0067538. Print 2013.

18.

Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.

Hirasawa A, Masuda K, Akahane T, Ueki A, Yokota M, Tsuruta T, Nomura H, Kataoka F, Tominaga E, Banno K, Makita K, Susumu N, Sugano K, Kosaki K, Kameyama K, Aoki D.

Jpn J Clin Oncol. 2014 Jan;44(1):49-56. doi: 10.1093/jjco/hyt171. Epub 2013 Nov 11.

PMID:
24218521

Supplemental Content

Support Center